IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients

What are the efficacy and safety profiles of IBI311, an insulin-like growth factor 1 receptor inhibitor, in Chinese patients with active thyroid eye disease (TED)?In this phase 3 randomized clinical trial, a significantly higher proportion of participants treated with IBI311 achieved a proptosis response compared with those receiving placebo at week 24, with no new safety issues not identified in previous clinical trials.Among Chinese adults with active TED, IBI311 demonstrated superiority on proptosis response compared with placebo, and the improvement was clinically relevant.

Corresponding Authors: Xianqun Fan, MD, PhD (drfanxianqun@126.com), and Huifang Zhou, MD, PhD (fangzzfang@sjtu.edu.cn), State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, No. 639 Zhizaoju Rd, Huangpu District, Shanghai 200011, China.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.